TNBC resistance to neoadjuvant chemotherapy
MD Anderson researchers discovered that triple negative breast cancer cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells.